CompletedNot Applicable

Dysferlinopathy Protein in Peripheral Blood Monocytes.

Spain149 participantsStarted 2012-02-01

Plain-language summary

The objective of the study is to answer the following important questions. Deficiency of the dysferlin protein is the cause of a very rare limb-girdle muscular dystrophy (LGMD-2B) that leads to significant disability. This disease is caused by mutations in the dysferlin gene. It is a recessive inherited disease, meaning that both copies of the gene must have mutations for the disease to develop. This study aims to analyze the frequency of carriers of a mutation in the DYSF gene in the Caucasian population. To achieve this, The investigator analyzed the blood of 100 healthy volunteers from their local area, quantifying the dysferlin protein in peripheral blood monocytes.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Individuals diagnosed with dysferlinopathies. * Carriers of a single mutation in the DYSF gene. * Participants who are willing to undergo treatment with oral vitamin D3. * Subjects who can provide informed consent for participation in the study. * Controls and carriers willing to participate in in vitro studies using HL60 cells, monocytes, and myotubes. Exclusion Criteria: * Individuals with conditions or medications that could interfere with the study outcomes of dysferlin expression. * Participants who are unwilling or unable to adhere to the study protocol for the duration of the study period. * Pregnant or breastfeeding women. * Individuals with known allergies or adverse reactions to vitamin D3 supplements. * Subjects with severe concurrent illnesses that may impact the study's objectives or their ability to participate effectively.

What they're measuring

Dysferlin Expression Levels by age and gender

Timeframe: 1 month

Trial details

NCT IDNCT06507215

SponsorFundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2012-02-27